The first coronavirus vaccine to enter human trials has returned “positive” results, its manufacturer said Monday
Moderna Therapeutics saw “positive” results from early vaccine tests. Photo: Aflo/Shutterstock . Moderna, the Boston-based biotech firm that began testing the vaccine in March, announced that eight healthy patients, who each received two doses of the vaccine, developed antibodies that fight the virus.
Because of the success of those two dose levels, Moderna will no longer test a single 250-microgram dose. Not only did that level trigger the most adverse side effects, but it’s not needed with the lower levels showing promise, chief medical officer Tal Zaks told the New York Times. Making the vaccine in lower doses will also allow more to be made, Zaks said.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Moderna coronavirus vaccine releases first human trial results - Business InsiderBusiness Insider is a fast-growing business site with deep financial, media, tech, and other industry verticals. Launched in 2007, the site is now the largest business news site on the web.
Weiterlesen »
Moderna's stock soars on positive early-stage data for its coronavirus vaccine candidateShares of Moderna Inc. jumped 25.1% in premarket trading on Monday after the biotechnology company announced positive results from a Phase 1 clinical trial for its experimental mRNA coronavirus vaccine. The trial was done in partnership with the National Institute of Allergy and Infectious Diseases. Within 43 days and after two doses, the participants taking one of two dosing levels of the vaccine candidate reported the same or higher level of antibodies as in blood samples gathered by patients who have recovered from COVID-19, the company said. There were four adverse events during the trial, including one participant who reported a severe skin reaction where the investigational vaccine was administered. "These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25" micrograms, Moderna chief medical officer Dr. Tal Zaks said in a news release. The next step is a Phase 2 trial, which has been approved to move forward by the Food and Drug Administration. It will focus on two dosing levels (50 microgram and 100 microgram). The early-stage trial had a third dosing level, 250 micrograms. Moderna's vaccine candidate is widely viewed as a frontrunner in the effort to develop the first vaccine for the virus. The preclinical company said earlier this month that the Phase 2 trial will begin "shortly," and on Monday it said it expects a Phase 3 trial to begin in July, if the vaccine is successful in the mid-stage trial. Moderna's stock has soared 240.9% year-to-date. The S&P 500 , in comparison, is down 11.3%.
Weiterlesen »
Coronavirus Vaccine Study Yields Positive Preliminary ResultsInitial results from a study of a COVID-19 vaccine suggest it is safe, and capable of generating the kind of immune response that may protect patients from getting the disease.
Weiterlesen »
5 things to know before the stock market opens MondayDow futures extend their gains and point to an over 600-point gain at Monday's open on positive coronavirus vaccine results.
Weiterlesen »
Moderna Says Initial Covid-19 Vaccine Results Are PositiveModerna said human subjects in a Phase 1 trial of a candidate Covid-19 vaccine produced immune responses that were a positive sign of the vaccine’s potential to prevent infection with the new coronavirus
Weiterlesen »
Coronavirus live updates: 'Positive' vaccine data lifts Moderna stock; Spain's GDP could fall more than 9.5%Covid-19 has now infected more than 4.7 million people around the world as of Monday, killing at least 315,496 people.
Weiterlesen »